Form 8-K BRISTOL MYERS SQUIBB CO For: Jul 26
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at Goldman Sachs
July 29, 2024 7:18 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $57.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "BMY's noteworthy outperformance on Friday July 26 (+~11% vs. flat XLV), while it occurred amidst favorable shifts in the broader market macro backdrop, was earned, in our... More
